Retinitis Pigmentosa Market 2025

Retinitis Pigmentosa Market Size

The global retinitis pigmentosa market reached a value of nearly $11,318.86 million in 2024, having grown at a compound annual growth rate (CAGR) of 5.14% since 2019. The market is expected to grow from $11,318.86 million in 2024 to $16,885.06 million in 2029 at a rate of 8.33%. The market is then expected to grow at a CAGR of 8.91% from 2029 and reach $25,878.31 million in 2034. Growth in the historic period resulted from government initiatives and funding, rising demand for personalized medicine, increasing focus on gene therapy research and expansion of genetic testing services. Factors that negatively affected growth in the historic period were the limited clinical trial participation and high treatment costs. Going forward, growing geriatric population, higher healthcare expenditure, rising investments in research and development and rising strategic collaborations and partnerships support will drive growth. Factor that could hinder the growth of the retinitis pigmentosa market in the future include were limited public and professional awareness and lack of healthcare infrastructure.

Retinitis Pigmentosa Market Drivers

The key drivers of the Retinitis Pigmentosa market include: Growing Geriatric Population A growing geriatric population is expected to propel the growth of the retinitis pigmentosa market during the forecast period. The geriatric population refers to individuals aged 65 years and older, often associated with increased healthcare needs, age-related conditions and specialized medical care. The geriatric population is growing due to increased life expectancy, advancements in healthcare, improved living conditions and better disease management. Additionally, declining birth rates in many countries result in a higher proportion of older adults in the population. The growing geriatric population drives the demand for retinitis pigmentosa treatments, as aging increases the prevalence and progression of vision-related disorders. For instance, in September 2024, according to the Age UK, a UK-based charity, the population of individuals aged 50 and above in England is expected to grow by 19.3% between 2024 and 2044, adding approximately 4.3 million people. Therefore, a growing geriatric population is expected to propel the growth of the retinitis pigmentosa market.

Retinitis Pigmentosa Market Restraints

The key restraints on the Retinitis Pigmentosa market include: Lack of Healthcare Infrastructure Lack of healthcare infrastructure is expected to hamper the growth of the retinitis pigmentosa market in the forecast period. Healthcare infrastructure refers to the physical, organizational and technological systems that support the delivery of medical services. This includes hospitals, clinics, diagnostic centers, medical equipment, healthcare professionals and digital health technologies. The lack of healthcare infrastructure restrained the management and treatment of retinitis pigmentosa (RP) by limiting access to essential diagnostic tools, specialized care and advanced therapies. Additionally, the absence of well-equipped medical facilities and research centers restricts the adoption of innovative treatments like gene therapy and retinal implants. For instance, in May 2024, according to the International Labour Organization, a Karger International Switzerland-based medical and scientific research publications, RP, the most common inherited retinal disease, affects approximately 1 in 4,000 people in the U.S. and 1 in 5,000 worldwide, with currently limited treatment options that primarily aim to slow its progression. Therefore, the lack of healthcare infrastructure will restrict the growth of the retinitis pigmentosa market.

Retinitis Pigmentosa Market Trends

Major trends shaping the Retinitis Pigmentosa market include: Strategic Collaborations Driving Advancements In Retinitis Pigmentosa Treatment Major companies in the retinitis pigmentosa market are focusing on adopting strategic collaborations to accelerate research, enhance gene therapy development and expand treatment access. Strategic collaborations refer to partnerships between biotech firms, pharmaceutical companies and research institutions to accelerate gene therapy development, optimize clinical trials and enhance treatment accessibility through data-driven insights and regulatory support. For instance, in February 2025, Verana Health, a US-based digital health company, partnered with Nanoscope Therapeutics Inc., a US-based biotechnology company, to accelerate research into retinitis pigmentosa (RP), a progressive retinal disease that can lead to blindness. By utilizing Verana's extensive Qdata Retinitis Pigmentosa dataset, which includes insights from over 70,000 de-identified patients, the collaboration aims to enhance the development of Nanoscope's optogenetic gene therapy, MCO-010. This partnership emphasizes the role of real-world data in improving clinical trial strategies and patient outcomes, ultimately paving the way for more effective treatments for individuals affected by RP. Regulatory Approvals Drive Advancements In Retinitis Pigmentosa Gene Therapies Leading companies in the retinitis pigmentosa market are prioritizing regulatory approvals to advance gene therapies, enhance treatment accessibility and accelerate commercial launches. These approvals, granted by health agencies such as the FDA (Food and Drug Administration) and EMA (European Medicines Agency), authorize clinical trials, manufacturing and marketing new treatments while ensuring safety, efficacy and quality. For example, in October 2024, Kiora Pharmaceuticals, Inc., a US-based pharmaceutical firm, secured approval to initiate ABACUS-2, a Phase 2 clinical trial of KIO-301 for retinitis pigmentosa. This multi-center, double-masked, randomized study will enroll 36 patients with ultra-low vision or no light perception. KIO-301, a molecular photoswitch, is designed to restore vision by making retinal cells light-responsive. The trial aligns with US and European regulatory expectations, with patients dosing anticipated next year. The trial's design and endpoints have been developed in consultation with European and US regulators to align with their expectations for approvable outcomes. Moreover, in April 2024, Ocugen, Inc., a US-based biotechnology company, secured FDA clearance for its IND amendment to launch a Phase 3 clinical trial for OCU400, the first gene therapy to reach Phase 3 with a broad retinitis pigmentosa (RP) indication. The trial will enroll 150 participants, including individuals with RHO gene mutations and a gene-agnostic group, in a randomized 2:1 treatment-to-control ratio. Effectiveness will be evaluated using the Luminance Dependent Navigation Assessment (LDNA), catering to patients at different RP stages.

Opportunities And Recommendations In The Retinitis Pigmentosa Market

Opportunities – The top opportunities in the retinitis pigmentosa market segmented by type will arise in the autosomal recessive segment, which will gain $2,809.90 million of global annual sales by 2029. The top opportunities in the retinitis pigmentosa market segmented by treatment will arise in the vitamin A segment, which will gain $1,617.62 million of global annual sales by 2029. The top opportunities in the retinitis pigmentosa market segmented by diagnosis will arise in the electroretinogram segment, which will gain $2,228.58 million of global annual sales by 2029. The top opportunities in the retinitis pigmentosa market segmented by distribution channel will arise in the online pharmacy segment, which will gain $2,515.12 million of global annual sales by 2029. The top opportunities in the retinitis pigmentosa market segmented by end-users will arise in the specialty clinics segment, which will gain $2,275.07 million of global annual sales by 2029. The retinitis pigmentosa market size will gain the most in the USA at $1,188.01 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the retinitis pigmentosa market companies to focus on advancing regulatory approvals and clinical trials, focus on advancing clinical trials for innovative therapies, focus on developing gene therapies through clinical trials, focus on the x-linked segment to accelerate growth, focus on gene therapy to capture the fastest growing opportunity, focus on genetic testing to leverage rapid diagnostic growth, expand in emerging markets, focus on strategic collaborations to accelerate research and treatment access, focus on value-based and tiered pricing to maximize market access and revenue, targeted awareness campaigns for retinitis pigmentosa companies, transparent communication on treatment efficacy and clinical trials, focus on online pharmacy to capture high-growth distribution opportunities, focus on specialty clinics to maximize end-user growth potential.